Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease
Identifieur interne : 006476 ( Main/Exploration ); précédent : 006475; suivant : 006477Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease
Auteurs : J. A. Temlett [Suisse] ; N. P. Quinn [Royaume-Uni] ; P. G. Jenner [Suisse] ; C. D. Marsden [Royaume-Uni] ; E. Pourcher [France] ; A. Bonnet [France] ; Yves Agid [France] ; R. Markstein [Suisse] ; X. Lataste [Suisse]Source :
- Movement Disorders [ 0885-3185 ] ; 1989.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Aged, Analgesics (therapeutic use), Animal, Animals, Antiparkinson agent, CY 208–243, Callitrichinae, Chemotherapy, D1 Dopamine receptor, Dopamine Agents (therapeutic use), Dopamine agonist, Dose activity relation, D‐1 Agonist Drugs, Experimental disease, Female, Human, Humans, Indoles (therapeutic use), Involuntary movement, Levodopa (therapeutic use), Male, Middle Aged, Monkey, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease, Secondary (chemically induced), Parkinson disease, Parkinson's Disease, Phenanthridines (therapeutic use), Pyridines, Subcutaneous administration, Tolerance, Treatment.
- MESH :
- chemical , therapeutic use : Analgesics, Dopamine Agents, Indoles, Levodopa, Phenanthridines.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Pyridines.
- chemically induced : Parkinson Disease, Secondary.
- drug therapy : Parkinson Disease.
- Aged, Animals, Callitrichinae, Female, Humans, Male, Middle Aged.
Abstract
The effect of stimulation of cerebral dopamine D‐1 receptors by CY 208‐243 on motor disability was tested in MPTP‐treated parkinsonian marmosets and patients with Parkinson's disease. CY 208‐243 (0.5–1.25 mg/kg s.c.) produced a dose‐related reversal of akinesia and rigidity in the marmosets, lasting some 2 h. Single morning doses of CY 208‐243 (5–40 mg) were compared with the usual morning dose of levodopa in eight patients with Parkinson's disease on long‐term levodopa therapy who had developed motor fluctuations from immobility with akinesia and rigidity (off) to mobility often with dyskinesias (on). CY 208‐243 alone was capable of switching such patients from off to on; five of the eight patients responded to the highest dose (40 mg), sometimes with dyskinesias. The response to CY 208‐243 was comparable to that produced by levodopa in these cases. Drugs designed to stimulate both dopamine D1 D2 receptors in the brain may improve the therapy of Parkinson's disease.
Url:
DOI: 10.1002/mds.870040307
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003197
- to stream Istex, to step Curation: 003197
- to stream Istex, to step Checkpoint: 004506
- to stream PubMed, to step Corpus: 004F92
- to stream PubMed, to step Curation: 004F92
- to stream PubMed, to step Checkpoint: 005002
- to stream Ncbi, to step Merge: 004264
- to stream Ncbi, to step Curation: 004264
- to stream Ncbi, to step Checkpoint: 004264
- to stream Main, to step Merge: 009829
- to stream PascalFrancis, to step Corpus: 003A22
- to stream PascalFrancis, to step Curation: 002E03
- to stream PascalFrancis, to step Checkpoint: 003A18
- to stream Main, to step Merge: 009880
- to stream Main, to step Curation: 006476
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease</title><author><name sortKey="Temlett, J A" sort="Temlett, J A" uniqKey="Temlett J" first="J. A." last="Temlett">J. A. Temlett</name></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name></author><author><name sortKey="Jenner, P G" sort="Jenner, P G" uniqKey="Jenner P" first="P. G." last="Jenner">P. G. Jenner</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></author><author><name sortKey="Pourcher, E" sort="Pourcher, E" uniqKey="Pourcher E" first="E." last="Pourcher">E. Pourcher</name></author><author><name sortKey="Bonnet, A" sort="Bonnet, A" uniqKey="Bonnet A" first="A." last="Bonnet">A. Bonnet</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Markstein, R" sort="Markstein, R" uniqKey="Markstein R" first="R." last="Markstein">R. Markstein</name></author><author><name sortKey="Lataste, X" sort="Lataste, X" uniqKey="Lataste X" first="X." last="Lataste">X. Lataste</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:530F1F5371C9E64C22CDB4DCB715F4F41282BA3C</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1002/mds.870040307</idno><idno type="url">https://api.istex.fr/document/530F1F5371C9E64C22CDB4DCB715F4F41282BA3C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003197</idno><idno type="wicri:Area/Istex/Curation">003197</idno><idno type="wicri:Area/Istex/Checkpoint">004506</idno><idno type="wicri:doubleKey">0885-3185:1989:Temlett J:antiparkinsonian:activity:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:2571082</idno><idno type="wicri:Area/PubMed/Corpus">004F92</idno><idno type="wicri:Area/PubMed/Curation">004F92</idno><idno type="wicri:Area/PubMed/Checkpoint">005002</idno><idno type="wicri:Area/Ncbi/Merge">004264</idno><idno type="wicri:Area/Ncbi/Curation">004264</idno><idno type="wicri:Area/Ncbi/Checkpoint">004264</idno><idno type="wicri:doubleKey">0885-3185:1989:Temlett J:antiparkinsonian:activity:of</idno><idno type="wicri:Area/Main/Merge">009829</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:90-0071783</idno><idno type="wicri:Area/PascalFrancis/Corpus">003A22</idno><idno type="wicri:Area/PascalFrancis/Curation">002E03</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003A18</idno><idno type="wicri:doubleKey">0885-3185:1989:Temlett J:antiparkinsonian:activity:of</idno><idno type="wicri:Area/Main/Merge">009880</idno><idno type="wicri:Area/Main/Curation">006476</idno><idno type="wicri:Area/Main/Exploration">006476</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease</title><author><name sortKey="Temlett, J A" sort="Temlett, J A" uniqKey="Temlett J" first="J. A." last="Temlett">J. A. Temlett</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>University Department of Neurology, Institute of Psychiatry and King's College School of Medicine and Dentistry</wicri:regionArea><wicri:noRegion>Institute of Psychiatry and King's College School of Medicine and Dentistry</wicri:noRegion></affiliation></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>The Institute of Neurology, Queen Square, London</wicri:cityArea></affiliation></author><author><name sortKey="Jenner, P G" sort="Jenner, P G" uniqKey="Jenner P" first="P. G." last="Jenner">P. G. Jenner</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>University Department of Neurology, Institute of Psychiatry and King's College School of Medicine and Dentistry</wicri:regionArea><wicri:noRegion>Institute of Psychiatry and King's College School of Medicine and Dentistry</wicri:noRegion></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>The Institute of Neurology, Queen Square, London</wicri:cityArea></affiliation></author><author><name sortKey="Pourcher, E" sort="Pourcher, E" uniqKey="Pourcher E" first="E." last="Pourcher">E. Pourcher</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Clinique de Neurologie et Neuropsychologie, INSERM U‐289, Hopital de la Salpetriere, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bonnet, A" sort="Bonnet, A" uniqKey="Bonnet A" first="A." last="Bonnet">A. Bonnet</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Clinique de Neurologie et Neuropsychologie, INSERM U‐289, Hopital de la Salpetriere, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Clinique de Neurologie et Neuropsychologie, INSERM U‐289, Hopital de la Salpetriere, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Markstein, R" sort="Markstein, R" uniqKey="Markstein R" first="R." last="Markstein">R. Markstein</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Sandoz Ltd, Basle</wicri:regionArea><wicri:noRegion>Basle</wicri:noRegion></affiliation></author><author><name sortKey="Lataste, X" sort="Lataste, X" uniqKey="Lataste X" first="X." last="Lataste">X. Lataste</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Sandoz Ltd, Basle</wicri:regionArea><wicri:noRegion>Basle</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1989">1989</date><biblScope unit="vol">4</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="261">261</biblScope><biblScope unit="page" to="265">265</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">530F1F5371C9E64C22CDB4DCB715F4F41282BA3C</idno><idno type="DOI">10.1002/mds.870040307</idno><idno type="ArticleID">MDS870040307</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Aged</term><term>Analgesics (therapeutic use)</term><term>Animal</term><term>Animals</term><term>Antiparkinson agent</term><term>CY 208–243</term><term>Callitrichinae</term><term>Chemotherapy</term><term>D1 Dopamine receptor</term><term>Dopamine Agents (therapeutic use)</term><term>Dopamine agonist</term><term>Dose activity relation</term><term>D‐1 Agonist Drugs</term><term>Experimental disease</term><term>Female</term><term>Human</term><term>Humans</term><term>Indoles (therapeutic use)</term><term>Involuntary movement</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Monkey</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson disease</term><term>Parkinson's Disease</term><term>Phenanthridines (therapeutic use)</term><term>Pyridines</term><term>Subcutaneous administration</term><term>Tolerance</term><term>Treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Analgesics</term><term>Dopamine Agents</term><term>Indoles</term><term>Levodopa</term><term>Phenanthridines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Pyridines</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Animals</term><term>Callitrichinae</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animal</term><term>Antiparkinsonien</term><term>CY 208243</term><term>Chimiothérapie</term><term>Homme</term><term>Mouvement involontaire</term><term>Parkinson maladie</term><term>Pathologie expérimentale</term><term>Relation dose réponse</term><term>Récepteur dopaminergique D1</term><term>Singe</term><term>Stimulant dopaminergique</term><term>Système nerveux pathologie</term><term>Tolérance</term><term>Traitement</term><term>Voie souscutanée</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Singe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The effect of stimulation of cerebral dopamine D‐1 receptors by CY 208‐243 on motor disability was tested in MPTP‐treated parkinsonian marmosets and patients with Parkinson's disease. CY 208‐243 (0.5–1.25 mg/kg s.c.) produced a dose‐related reversal of akinesia and rigidity in the marmosets, lasting some 2 h. Single morning doses of CY 208‐243 (5–40 mg) were compared with the usual morning dose of levodopa in eight patients with Parkinson's disease on long‐term levodopa therapy who had developed motor fluctuations from immobility with akinesia and rigidity (off) to mobility often with dyskinesias (on). CY 208‐243 alone was capable of switching such patients from off to on; five of the eight patients responded to the highest dose (40 mg), sometimes with dyskinesias. The response to CY 208‐243 was comparable to that produced by levodopa in these cases. Drugs designed to stimulate both dopamine D1 D2 receptors in the brain may improve the therapy of Parkinson's disease.</div></front></TEI><affiliations><list><country><li>France</li><li>Royaume-Uni</li><li>Suisse</li></country><region><li>Angleterre</li><li>Île-de-France</li></region><settlement><li>Paris</li></settlement><orgName><li>Hôpital de la Salpêtrière</li></orgName></list><tree><country name="Suisse"><noRegion><name sortKey="Temlett, J A" sort="Temlett, J A" uniqKey="Temlett J" first="J. A." last="Temlett">J. A. Temlett</name></noRegion><name sortKey="Jenner, P G" sort="Jenner, P G" uniqKey="Jenner P" first="P. G." last="Jenner">P. G. Jenner</name><name sortKey="Lataste, X" sort="Lataste, X" uniqKey="Lataste X" first="X." last="Lataste">X. Lataste</name><name sortKey="Markstein, R" sort="Markstein, R" uniqKey="Markstein R" first="R." last="Markstein">R. Markstein</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name></region><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></country><country name="France"><noRegion><name sortKey="Pourcher, E" sort="Pourcher, E" uniqKey="Pourcher E" first="E." last="Pourcher">E. Pourcher</name></noRegion><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><name sortKey="Bonnet, A" sort="Bonnet, A" uniqKey="Bonnet A" first="A." last="Bonnet">A. Bonnet</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006476 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006476 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:530F1F5371C9E64C22CDB4DCB715F4F41282BA3C
|texte= Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |